Search

… Job Title Nurse Practitioner I joined Memorial Sloan Kettering as an oncology nurse in 2005 and became a nurse practitioner in 2011. I have had the opportunity to become proficient in the care of many different oncology patient populations, including people undergoing head and neck surgery, thoracic

The Sarcoma Center at Memorial Sloan Kettering has access to a number of resources that enable the advancement of sarcoma research.

… The Sarcoma Center at Memorial Sloan Kettering has a number of critical resources available that facilitate innovation in this vital field of research. One of the resources available to the Sarcoma Center is a database of soft tissue sarcoma cases. The database was developed in 1982 by Sir Murray Brennan

Learn about the work Memorial Sloan Kettering scientists are doing in the area of computational oncology.

… Next-generation sequencing has enabled scientists to collect an astonishing amount of data about the genomes of both normal and cancerous cells. Through computational oncology, our investigators are creating tools that enable them to navigate and analyze this vast quantity of information and translate

… Job Title Research Scientist at DeepMind, London

… Job Title Research Technician

Learn how to contact the MSK Center for Epigenetics Research (CER).

… If you would like more information about the Center for Epigenetics Research (CER) or wish to support our research, please contact: Iestyn Whitehouse, PhD Director, Center for Epigenetics Research Memorial Sloan Kettering Cancer Center 1275 York Avenue, RRL-817C New York, NY 10065, USA Office:  646-239

… Job Title Senior Administrative Assistant Start Year 2018 Email [email protected] Office Phone 646-888-2820

Read about an FDA approval for immunotherapy to treat head and neck squamous cell carcinoma.

… Wednesday, October 1, 2025 People with locally advanced  head and neck squamous cell carcinoma (HNSCC) now have a new treatment option that could extend their lives with fewer side effects. The  U.S. Food and Drug Administration (FDA) has approved the immunotherapy drug  pembrolizumab (Keytruda® ) to

… Full Title A Phase 2 Study of SNDX-5613 in Combination with Chemotherapy for Patients with Relapsed or Refractory KMT2A-Rearranged Infant Leukemia (AALL2121) (CIRB) Purpose Researchers want to see how well revumenib works when given with chemotherapy to treat infant leukemia. The children in this study